Showing 1 to 2 of 2 results


Novo Nordisk Shares Plunge on Lowered Profit Outlook Amidst Copycat Drug Competition
Novo Nordisk shares fell over 20% on Tuesday after the company announced a new CEO and lowered its profit expectations, citing weaker sales of its weight-loss drug Wegovy due to competition from copycat drugs; the company expects 8%-14% sales growth and 10%-16% operating profit growth for 2025.
Novo Nordisk Shares Plunge on Lowered Profit Outlook Amidst Copycat Drug Competition
Novo Nordisk shares fell over 20% on Tuesday after the company announced a new CEO and lowered its profit expectations, citing weaker sales of its weight-loss drug Wegovy due to competition from copycat drugs; the company expects 8%-14% sales growth and 10%-16% operating profit growth for 2025.
Progress
44% Bias Score

Novo Nordisk Cuts Forecasts Amid Copycat Weight-Loss Drug Surge
Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, cut its sales and profit forecasts due to competition from copycat weight-loss drugs made by compounding pharmacies in the US, which captured about a third of the market despite a forthcoming ban and the company exceeding first...

Novo Nordisk Cuts Forecasts Amid Copycat Weight-Loss Drug Surge
Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, cut its sales and profit forecasts due to competition from copycat weight-loss drugs made by compounding pharmacies in the US, which captured about a third of the market despite a forthcoming ban and the company exceeding first...
Progress
40% Bias Score
Showing 1 to 2 of 2 results